Enspryng Side Effects

Generic name: satralizumab

Medically reviewed by Drugs.com. Last updated on Mar 11, 2023.

Note: This document contains side effect information about satralizumab. Some dosage forms listed on this page may not apply to the brand name Enspryng.

Applies to satralizumab: subcutaneous solution.

Serious side effects of Enspryng

Along with its needed effects, satralizumab (the active ingredient contained in Enspryng) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking satralizumab:

More common

Black, tarry stools
body aches or pain
burning feeling in the chest or stomach
chills
cough
dark urine
depression
difficulty in moving
dryness or soreness of the throat
ear congestion
falls
fever
headache
hoarseness
indigestion
joint pain
light-colored stools
loss of voice
lower back or side pain
muscle pain or stiffness
nausea and vomiting
painful or difficult urination
pain, redness, swelling, tenderness, or warmth on the skin
pale skin
skin rash, hives, itching
sneezing
sore throat
stomach upset
stuffy or runny nose
tenderness in the stomach area
tender, swollen glands in the neck
trouble breathing or swallowing
ulcers, sores, or white spots in the mouth
unusual bleeding or bruising
unusual tiredness or weakness
upper right stomach pain
weight gain
yellow eyes and skin

Other side effects of Enspryng

Some side effects of satralizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to satralizumab: subcutaneous solution.

Hematologic

Very common (10% or more): Neutropenia (10%), blood creatine phosphokinase^[Ref]

Immunologic

Very common (10% or more): Cellulitis (10%)

Frequency not reported: Potential for immunogenicity^[Ref]

Local

Frequency not reported: Injection site reaction, skin mass^[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (17%), pain in extremity (15%)^[Ref]

Metabolic

Very common (10% or more): Weight gain (30%), cholesterol increased (15%)^[Ref]

Psychiatric

Very common (10% or more): Depression (10%)^[Ref]

Hepatic

Very common (10% or more): Fibrinogen levels increased (38%), ALT and AST elevated (43%)^[Ref]

Respiratory

Very common (10% or more): Nasopharyngitis (31%), upper respiratory tract infection (19%), pharyngitis (12%)^[Ref]

Other

Very common (10% or more): Fatigue (15%), fall (10%)^[Ref]

General

The most common adverse reactions (15% or greater) were nasopharyngitis, headache, upper respiratory tract infection, gastritis, rash, arthralgia, extremity pain, fatigue, and nausea.^[Ref]